Elsevier

Clinical Therapeutics

Volume 30, Issue 6, June 2008, Pages 1145-1154
Clinical Therapeutics

A retrospective analysis of the prevalence and treatment of hypertension and dyslipidemia in Southwestern Ontario, Canada

https://doi.org/10.1016/j.clinthera.2008.06.004Get rights and content

Abstract

Background: Previous evaluations of the Southwestern Ontario (SSWO) cohort have reported that hypertension (HTN) and dyslipidemia (DYS) are undertreated illnesses; however, concomitant treatment is unknown.

Objectives: The objectives of this study were to assess the prevalence and associated treatment of HTN and DYS in primary health care in SWO and to identify care gaps across subpopulations.

Methods: In this retrospective cohort analysis, chart-abstracted medical records of patients aged ≧118 years with a clinical diagnosis of HTN, DYS, or both and the clinical practice records of primary health care facilities in London, Ontario, Canada, and the surrounding area were conducted between April and December 2000; longitudinal updates were performed quarterly until December 2004. Chart-abstracted information included demographics, lifestyle (eg, diet, exercise), cardiovascular disease indicators, complete morbidity profile, and drug treatments and effects.

Results: The medical records of 46,322 patients who received medical care and the clinical practice records of 37 primary health care facilities (where the patients received treatment) in London, Ontario, Canada, and the surrounding area were included in this study. Our analyses found that the prevalence of HTN (17.66%) was greater than that of DYS (12.33%); with comorbid HTN and DYS found in 8.0% of the population. Most hypertensive patients were not dyslipidemic (54.88%), but more than half of dyslipidemic patients had comorbid HTN (64.99%). Significant differences in prevalence among the sex, age, and comorbid subgroups were found. HTN was higher among females than males (P<0.001) but lower among female smokers than male smokers (P<0.001). Patients aged >55 years were much more likely to be hypertensive, dyslipidemic, or both compared with those aged <55 years (P<0.009), except among those patients with a family history of coronary heart disease (CHD). Additionally, a steady increase in HTN and DYS prevalence with age by decade until 75 years of age, after which the rates dropped off, was observed. Most patients were untreated for HTN (66.00%) or DYS (80.00%) unless both conditions were present (35.00% untreated for HTN; 39.00% untreated for DYS). Among patients with comorbid HTN and DYS, the order of diagnosis had a significant effect on treatment level. The presence of other comorbidities (eg, family history of CHD) resulted in higher treatment and control rates. Control levels were generally poor, with 7.0% among patients with DYS, 15.00% among patients with HTN, and 17.00% among patients with both conditions.

Conclusions: Treatment patterns of HTN and DYS in practice settings are not in alignment with current guidelines in this cohort. Pharmacologic treatment of HTN and DYS is underprescribed. Patients most likely to receive treatment have comorbidities, but even in those high-risk groups, treatment levels are low and recommended control levels even lower.

References (17)

There are more references available in the full text version of this article.

Cited by (23)

  • The impact of cardiovascular risk-factor profiles on blood pressure control rates in adults from Canada and the United States

    2013, Canadian Journal of Cardiology
    Citation Excerpt :

    However, our more important finding was that despite concerns that patients with multiple comorbidities may have their BP less well treated,8 we found that BP control rates actually improved as the number of other risk factors increased in both Canada and the United States. This pattern was also reported in medical record audits from a group of primary care practices in Southwestern Ontario in 200421 but has not been seen in other jurisdictions.22,23 Thus, while control rates for hypertension have improved markedly in both Canada12 and the United States24 during the past 2 decades, the persistently high prevalence of additional CV risk factors in hypertensive individuals will blunt the potential magnitude of the reductions in CV morbidity and mortality that would have been expected otherwise.

  • Treating Hypertension to Reduce Cardiovascular Risk: A Korean Perspective

    2012, Clinical Therapeutics
    Citation Excerpt :

    Furthermore, strategies to improve hypertension treatment may be effective in reducing the global risk of cardiovascular events not only by improving blood pressure control but also by improving the control of other risk factors such as diabetes mellitus and hypercholesterolemia. Hypertension usually clusters with other cardiovascular risk factors, such as insulin resistance, visceral obesity, and dyslipidemia.16 The clustering of cardiovascular risk factors greatly increases an individual's risk for cardiovascular morbidity and mortality.17

  • Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades

    2011, CMAJ. Canadian Medical Association Journal
    Citation Excerpt :

    This is encouraging, as it suggests that either Canadian physicians appropriately target more intensive therapy to patients at higher risk or that patients at higher risk are more compliant with their therapy. A similar result was seen in a chart audit of more than 10 000 patients from primary care practices in southwestern Ontario,24 but such a result has not been seen in other countries.25–27 This is important, as targeting therapy toward people with established disease or multiple cardiovascular risk factors will lead to greater absolute benefits than treatment strategies targeting only single risk factors.28

View all citing articles on Scopus
View full text